JS InnoPharm Ltd is Drug Discovery in China that focus on molecule tumor business. Founded in 2010. They cover business area such as provider, outsourcing service, new drug, molecular drug design, drug synthesis, vivo and in vitro biological activity evaluation, ADMET, Absorption, Distribution, Metabolism, Excretion, Toxicity, testing, medical institution, small molecule tumor immune drug, oncology drug.
2010
( 14 years old in 2024 )
Molecule Tumor
-
Floor 3, Building 1
No. 400 Fangchun Road, China (Shanghai) Pilot Free Trade Zone
Shanghai
China
Private
provideroutsourcing servicenew drugmolecular drug designdrug synthesisvivo and in vitro biological activity evaluationADMETAbsorptionDistributionMetabolismExcretionToxicitytestingmedical institutionsmall molecule tumor immune drugoncology drug
* We use standard office opening hours in near JS InnoPharm Ltd's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
JS InnoPharm Ltd is Drug Discovery business from China that founded in 2010 (14 years old in 2024), JS InnoPharm Ltd business is focusing on Molecule Tumor.
JS InnoPharm Ltd headquarter office and corporate office address is located in Floor 3, Building 1 No. 400 Fangchun Road, China (Shanghai) Pilot Free Trade Zone Shanghai China.
JS InnoPharm Ltd was founded in China.
In 2024, JS InnoPharm Ltd is currently focus on molecule tumor sector.
Above is snippet of Google Trends for "molecule tumor" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with JS InnoPharm Ltd, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
